Meropenem and EDTAThird Party Manufacturing in India

The combination of Meropenem and EDTA works by overcoming specific forms of bacterial resistance, particularly metallo-beta-lactamases (MBLs).

Meropenem is a broad-spectrum carbapenem that inhibits bacterial cell wall synthesis by binding to essential penicillin-binding proteins (PBPs). EDTA (Ethylenediaminetetraacetic acid) acts as a chelating agent and an efflux pump inhibitor. It chelates divalent cations like zinc, which are crucial for the structural integrity of MBLs, thereby deactivating these resistance enzymes. EDTA also increases the permeability of the bacterial outer membrane.

Unlike standard carbapenems, this combination provides targeted efficacy against multidrug-resistant Gram-negative bacteria, offering a vital defense in critical care environments.

Therapeutic Uses

Meropenem and EDTA are prescribed for the treatment of:

• Multidrug-Resistant Infections: Specifically targets infections caused by metallo-beta-lactamase (MBL) producing Gram-negative pathogens.
• Complicated Intra-Abdominal Infections: Efficacious in mixed infections with highly resistant strains.
• Severe Hospital-Acquired Pneumonia: Provides an essential therapeutic option when standard antibiotics fail.

Why Manufacturers Choose Meropenem and EDTA

The emergence of carbapenemase-producing bacteria is a major global health challenge. EDTA's ability to inhibit MBLs synergistically restores meropenem's potency, creating a highly specialized and vital therapeutic option.

This makes the Meropenem and EDTA combination a highly sought-after, niche molecule for third party manufacturing in India, appealing to advanced critical care and specialized franchise divisions.